Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AmpliPhi Establishes Collaboration with Intrexon

Published: Thursday, April 18, 2013
Last Updated: Thursday, April 18, 2013
Bookmark and Share
Combined expertise to create new generation of bacteriophage-based therapeutics for antibiotic resistant infections.

AmpliPhi BioSciences Corp. and Intrexon Corporation have announced the formation of an exclusive channel collaboration (“ECC”) to develop new bacteriophage-based therapies to target specific antibiotic resistant infections, some of the most widespread and deadly types of infections.

The collaboration seeks to develop bacteriophage-containing human therapeutics for use in the treatment of bacterial infections associated with acute and chronic wounds, the treatment of acute and chronic P aeruginosa lung infections, and the treatment of infections of C. difficile.

Philip J. Young, President and Chief Executive Officer of AmpliPhi, said, “The global market for anti-infective therapies is expected to reach $40 billion annually by 2014. Combining Intrexon’s synthetic biology technologies with our phage development expertise gives us the opportunity to develop and bring to market an important new generation of anti-infective therapies that have the potential to save or change the lives of millions of people.”

Randal J. Kirk, CEO and Chairman of the Board of Intrexon, added, “This collaboration with AmpliPhi should at last make practical the long-appreciated therapeutic potential of phage therapies, resulting in an armamentarium of new treatments for infectious diseases. We are delighted to get underway on this exciting program.”

Under the terms of the ECC agreement, AmpliPhi will receive an exclusive, worldwide license to utilize Intrexon’s proprietary technology and expertise toward the standardized production of wild type phages, as well as for the design and production of genetically modified bacteriophages.

Intrexon will apply its proprietary technologies, including the UltraVector® platform, DNA and RNA MOD engineering, protein engineering, inducible gene systems, genome engineering, and cell systems engineering, to AmpliPhi’s bacteriophage programs.

AmpliPhi will issue to Intrexon 24,000,000 shares of its common stock (representing approximately 26% of Ampliphi’s outstanding shares after the issuance).

The ECC also includes the potential for development milestones that are payable in equity or cash. In addition, AmpliPhi will pay Intrexon royalties on the net sales of products developed under the ECC.

Griffin Securities served as financial advisor to Intrexon in connection with the transaction.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AmpliPhi Announces the Appointment of Baxter Phillips
Industry leader brings broad strategic and licensing experience in development and commercial stage biopharmaceutical companies.
Thursday, November 14, 2013
AmpliPhi Signs Exclusive License With University of Leicester, UK
Collaboration and license agreement to develop bacteriophage therapies targeting Clostridium difficile.
Friday, October 18, 2013
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Apricot Kernels Pose Risk of Cyanide Poisoning
Eating more than three small raw apricot kernels, or less than half of one large kernel, in a serving can exceed safe levels. Toddlers consuming even one small apricot kernel risk being over the safe level.
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Genetic Markers Influence Addiction
Differences in vulnerability to cocaine addiction and relapse linked to both inherited traits and epigenetics, U-M researchers find.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
A lncRNA Regulates Repair of DNA Breaks in Breast Cancer Cells
Findings give "new insight" into biology of tough-to-treat breast cancer.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!